Clinical trial
Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in…
NCT00310817 · Novartis Vaccines, Industry · Completed
Key facts
| NCT number | NCT00310817 |
|---|---|
| Title | Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. |
| Official title | A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. |
| Lead sponsor | Novartis Vaccines, Industry |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Meningococcal Meningitis |
| Intervention type | Biological |
| Interventions | MenACWY-CRM conjugate vaccine, adjuvanted, MenACWY polysaccharide vaccine, unadjuvanted |
| Enrollment | 623 |
| Start date | Mar 1, 2005 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Apr 5, 2006 |
| Last update posted | Nov 6, 2015 |
| Countries | Finland, Poland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: